E Torres Suárez1, R Pinheiro2, N Schrage2. 1. Augenklinik, Krankenhaus Merheim, Kliniken der Stadt Köln, Ostmerheimer Str. 200, 51109, Köln, Deutschland. elenatorres@web.de. 2. Augenklinik, Krankenhaus Merheim, Kliniken der Stadt Köln, Ostmerheimer Str. 200, 51109, Köln, Deutschland.
Abstract
BACKGROUND: Interferon α‑2b (IFN α‑2b) is an established and well-tolerated treatment for ocular surface squamous neoplasia (OSSN). METHOD: Report of complications in two patients with OSSN and rheumatoid arthritis treated with adjuvant topical IFN α‑2b. RESULTS: One patient developed a scleral melt and the other one severe keratitis. After discontinuing treatment with IFN α‑2b both patients showed considerable improvement. CONCLUSION: Immunosuppressed patients with OSSN under topical IFN α‑2b should be closely monitored for early detection of complications.
BACKGROUND: Interferon α‑2b (IFN α‑2b) is an established and well-tolerated treatment for ocular surface squamous neoplasia (OSSN). METHOD: Report of complications in two patients with OSSN and rheumatoid arthritis treated with adjuvant topical IFN α‑2b. RESULTS: One patient developed a scleral melt and the other one severe keratitis. After discontinuing treatment with IFN α‑2b both patients showed considerable improvement. CONCLUSION: Immunosuppressed patients with OSSN under topical IFN α‑2b should be closely monitored for early detection of complications.
Authors: Afshan A Nanji; Christina S Moon; Anat Galor; Julia Sein; Patrick Oellers; Carol L Karp Journal: Ophthalmology Date: 2014-01-09 Impact factor: 12.079
Authors: Carol L Shields; Swathi Kaliki; H Jane Kim; Saad Al-Dahmash; Sanket U Shah; Sara E Lally; Jerry A Shields Journal: Cornea Date: 2013-03 Impact factor: 2.651